Morfin Sad (Morphine Hydrochloride Trihydrate)

Morphine acts as an agonist at mu‑opioid receptors in the central nervous system. By activating these receptors, it inhibits the release of excitatory neurotransmitters, reduces neuronal firing, and diminishes the perception of pain, resulting in analgesia and a degree of sedation.

The appropriate dose of Morfin Sad is determined by the prescribing clinician based on the patient’s pain severity, weight, renal and hepatic function, and prior opioid exposure. Dosage regimens are individualized and should follow local clinical guidelines and the product’s prescribing information.

Morphine crosses the placenta and is excreted in breast milk. Use during pregnancy or lactation is only recommended when the potential benefit to the mother outweighs the possible risk to the fetus or infant. Clinicians should discuss alternatives and closely monitor any exposure.

To place an order, submit an enquiry on the Morfin Sad product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with other opioids such as fentanyl or hydromorphone, morphine has a longer history of use and a well‑characterized safety profile. It provides effective analgesia but may have a higher incidence of certain side effects like constipation and histamine‑mediated itching. Choice of agent depends on clinical context, potency needs, and patient tolerance.

Morfin Sad should be stored below 25 °C in its original packaging, protected from moisture and direct light. Ensure the container remains tightly sealed and avoid exposure to extreme temperatures. Follow standard pharmaceutical handling procedures to maintain product integrity.

Morfin Sad is administered by a qualified healthcare professional via the epidural route. The medication is injected into the epidural space using aseptic technique, allowing the drug to act directly on spinal opioid receptors for targeted analgesia. Dosage and infusion rate are set by the prescriber.

The most critical risks include respiratory depression, severe hypotension, and the potential for dependence or abuse with prolonged use. Clinicians must monitor respiratory function, blood pressure, and signs of opioid tolerance, especially in patients with pre‑existing respiratory conditions or when combined with other depressants.

Morfin Sad is contraindicated in patients with known hypersensitivity to morphine or any component of the formulation, those with severe respiratory insufficiency, acute or severe bronchial asthma, and patients who have taken monoamine oxidase inhibitors within the past 14 days. Caution is also advised for individuals with uncontrolled hypertension or significant head injury.